These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 19628161)

  • 1. HCV NS5B polymerase inhibitors.
    Burton JR; Everson GT
    Clin Liver Dis; 2009 Aug; 13(3):453-65. PubMed ID: 19628161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New NS5B polymerase inhibitors for hepatitis C.
    Legrand-Abravanel F; Nicot F; Izopet J
    Expert Opin Investig Drugs; 2010 Aug; 19(8):963-75. PubMed ID: 20629614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. R-1626, a specific oral NS5B polymerase inhibitor of hepatitis C virus.
    Toniutto P; Fabris C; Bitetto D; Fumolo E; Fornasiere E; Pirisi M
    IDrugs; 2008 Oct; 11(10):738-49. PubMed ID: 18828074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New targets for antiviral therapy of chronic hepatitis C.
    Bühler S; Bartenschlager R
    Liver Int; 2012 Feb; 32 Suppl 1():9-16. PubMed ID: 22212566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection.
    Zeuzem S; Asselah T; Angus P; Zarski JP; Larrey D; Müllhaupt B; Gane E; Schuchmann M; Lohse A; Pol S; Bronowicki JP; Roberts S; Arasteh K; Zoulim F; Heim M; Stern JO; Kukolj G; Nehmiz G; Haefner C; Boecher WO
    Gastroenterology; 2011 Dec; 141(6):2047-55; quiz e14. PubMed ID: 21925126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in the development of anti-hepatitis C virus nucleoside and nucleotide prodrugs.
    Madela K; McGuigan C
    Future Med Chem; 2012 Apr; 4(5):625-50. PubMed ID: 22458682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.
    Beaulieu PL
    IDrugs; 2010 Dec; 13(12):938-48. PubMed ID: 21154154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].
    Şanlıdağ T; Sayan M; Akçalı S; Kasap E; Buran T; Arıkan A
    Mikrobiyol Bul; 2017 Apr; 51(2):145-155. PubMed ID: 28566078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current perspective of HCV NS5B inhibitors: a review.
    Patil VM; Gupta SP; Samanta S; Masand N
    Curr Med Chem; 2011; 18(36):5564-97. PubMed ID: 22172066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase.
    Sofia MJ; Chang W; Furman PA; Mosley RT; Ross BS
    J Med Chem; 2012 Mar; 55(6):2481-531. PubMed ID: 22185586
    [No Abstract]   [Full Text] [Related]  

  • 11. Combinations of cyclophilin inhibitor NIM811 with hepatitis C Virus NS3-4A Protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance.
    Mathy JE; Ma S; Compton T; Lin K
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3267-75. PubMed ID: 18591281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C therapy with HCV NS5B polymerase inhibitors.
    Soriano V; Vispo E; de Mendoza C; Labarga P; Fernandez-Montero JV; Poveda E; Treviño A; Barreiro P
    Expert Opin Pharmacother; 2013 Jun; 14(9):1161-70. PubMed ID: 23621117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors.
    Wyles DL; Kaihara KA; Schooley RT
    Antimicrob Agents Chemother; 2008 May; 52(5):1862-4. PubMed ID: 18332167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral strategies in hepatitis C virus infection.
    Sarrazin C; Hézode C; Zeuzem S; Pawlotsky JM
    J Hepatol; 2012; 56 Suppl 1():S88-100. PubMed ID: 22300469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus protease inhibitor-resistance mutations: our experience and review.
    Wu S; Kanda T; Nakamoto S; Imazeki F; Yokosuka O
    World J Gastroenterol; 2013 Dec; 19(47):8940-8. PubMed ID: 24379619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus NS3 inhibitors: current and future perspectives.
    Salam KA; Akimitsu N
    Biomed Res Int; 2013; 2013():467869. PubMed ID: 24282816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in discovery and development of promising therapeutics against hepatitis C virus NS5B RNA-dependent RNA polymerase.
    Wu JZ; Yao N; Walker M; Hong Z
    Mini Rev Med Chem; 2005 Dec; 5(12):1103-12. PubMed ID: 16375756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sofosbuvir (Sovaldi°). Active against hepatitis C virus, but evaluation is incomplete .
    Prescrire Int; 2015 Jan; 24(156):5-10. PubMed ID: 25734194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antiviral treatment of chronic hepatitis C].
    Berger A
    Med Monatsschr Pharm; 2012 Feb; 35(2):55-60. PubMed ID: 22400430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What future for ribavirin?
    Shiffman ML
    Liver Int; 2009 Jan; 29 Suppl 1():68-73. PubMed ID: 19207968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.